Gentuximab + Paclitaxel
Phase 1/2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 28/100
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Gastric or Gastroesophageal Junction Cancer
Conditions
Advanced Gastric or Gastroesophageal Junction Cancer
Trial Timeline
Aug 1, 2019 → Dec 1, 2020
NCT ID
NCT04053205About Gentuximab + Paclitaxel
Gentuximab + Paclitaxel is a phase 1/2 stage product being developed by Sun Pharmaceutical for Advanced Gastric or Gastroesophageal Junction Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04053205. Target conditions include Advanced Gastric or Gastroesophageal Junction Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Gastric or Gastroesophageal Junction Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04053205 | Phase 1/2 | UNKNOWN |
Competing Products
20 competing products in Advanced Gastric or Gastroesophageal Junction Cancer